HSIC Henry Schein, Inc.
Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as provides equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting, and other services. It also markets and sells a portfolio of consumable merchandise under its own corporate brand. The Global Specialty Products segment engage in manufacturing, marketing, and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products, and other health care-related products and services. The Global Technology segment is involved in the development and distribution of practice management software, e-services, and other products which are distributed to health care providers. The company serves dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics. It has a strategic partnership with GoTu Technology to help dental practices address ongoing staffing challenges. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.…
Industry Peers
Medical DistributionKey Statistics
About Henry Schein (NASDAQ: HSIC)
›
Henry Schein (NASDAQ: HSIC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Distribution industry, part of the Healthcare sector, and reports about 25,000 employees.
The shares were at 84.80 USD on 19 November 2026, up 21.0% over 52 weeks. Its 52-week range is 68.70 USD to 92.18 USD: the price is 8.0% below the high and 23.4% above the low.
At a market capitalisation of 9.37B USD, it trades at 23.2 times trailing earnings and 14.1 times forward earnings. The median trailing P/E of its 17 largest Medical Distribution peers is 20.3, a premium of 15% for HSIC.
Henry Schein reports return on equity of 12.3%, an operating margin of 5.8% and revenue up 4.0% year over year.
Its debt exceeds its cash by 3.71B USD, a debt-to-equity ratio of 1.06. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 15 analysts cover the stock, with an average rating of Buy; their mean price target of 96.87 USD is 14.2% above the current price. The next earnings report is expected on 23 February 2027.